Document:

Exhibit 10.7

 

Execution Version

 

 

December 10, 2020

 

Neos Therapeutics, Inc.

2940 N. Hwy 360, Suite 400

Grand Prairie, Texas 75050

Attention: Richard Eisenstadt

 

Aytu Bioscience, Inc.

373 Inverness Parkway, Suite 206

Englewood, Colorado 80112

Attention: Joshua Disbrow

 

		Re:	Commitment Letter

 

Ladies and
Gentlemen:

 

Reference is made to
that certain Loan and Security Agreement dated as of October 2, 2019 (as amended, restated, supplemented or otherwise modified
from time to time, the "Loan Agreement"), by and among NEOS THERAPEUTICS, INC., a Delaware corporation
("Company"), NEOS THERAPEUTICS BRANDS, LLC, a Delaware limited liability company ("NT Brands"),
NEOS THERAPEUTICS, LP, a Texas limited partnership ("NT LP"; together with Company, NT Brands and each
other Person who joins this Agreement as a borrower from time to time, each a "Borrower" and collectively
the "Borrowers"), NEOS THERAPEUTICS COMMERCIAL, LLC, a Delaware limited liability company ("NT
Commercial"), and PHARMAFAB TEXAS, LLC, a Texas limited liability company ("NT PharmaFab"),
as Loan Party Obligors, the Lenders party thereto from time to time and ENCINA BUSINESS
CREDIT, LLC, as agent for the Lenders (in such capacity, "Agent"). Capitalized terms used but not
defined herein shall have the meanings given to them in the Loan Agreement.

 

Borrowers have informed
Agent and Lenders that Company desires to enter into that certain Merger Agreement of even date herewith by and among Company,
Aytu Bioscience, Inc., a Delaware corporation ("Aytu"), and Neutron Acquisition Sub, Inc., a Delaware corporation,
dated as of the date hereof (the "Merger Agreement"), pursuant to which, subject to the terms and conditions
set forth therein, Aytu intends to acquire the Company such that, after giving effect to such merger, Company and each other Loan
Party shall be wholly-owned direct or indirect subsidiaries of Aytu (the "Proposed Merger Transaction").
Absent the consent of Agent and Lenders, consummation of the Proposed Merger Transaction would constitute an Event of Default under
Section 11.1(l) of the Loan Agreement. Borrowers have requested that Agent and Lenders provide their consent to the entry into
and consummation by the Borrowers of the Proposed Merger Transaction.

 

     

     

    

 

In
addition, Borrowers have informed Agent and Lenders that, in connection with the Proposed Merger Transaction, Borrowers desire
to (i) issue a Unsecured Convertible Promissory Note to Aytu in
a maximum principal amount of up to $5,000,000 (the "Specified Subordinated Note"), (ii) upon consummation
of the Proposed Merger Transaction, make a prepayment of up to $15,000,000 of principal
in respect of the Term Loan Debt plus any interest thereon that would have otherwise accrued through May 11, 2021 (collectively,
the "Specified Term Loan Prepayment") and (iii) make certain modifications to the Term Loan Debt, which
are described in the letter agreement, dated as of the date hereof, among the Company, Aytu and Deerfield Private Design Fund II,
L.P. and Deerfield Partners, L.P (in the form attached hereto as Exhibit B, the "Term Loan Debt Commitment Letter").
Absent the consent of Agent and Lenders, these transactions would be prohibited under the terms of the Loan Agreement and the Term
Loan Intercreditor Agreement, respectively.

 

Borrowers
have requested that Agent and Lenders, (1) provide their consent to the incurrence of indebtedness under the Specified Subordinated
Note, and (2) on the Closing Date (as defined in the Merger Agreement), (a) provide their consent to (i) the change of control
that will result from the consummation of the Proposed Merger Transaction in accordance with the Merger Agreement, (ii) the making
of the Specified Term Loan Prepayment and (iii) the modifications to the Term Loan Debt as contemplated under the Term Loan Debt
Commitment Letter and (b) irrevocably waive (i) the "going concern" Event of Default under Section 7.15(a) of the Loan
Agreement (as more specifically described in that certain letter agreement by and among Agent, Lenders, Borrowers and Loan Party
Obligors dated as of the date hereof) (the "Specified Default") and (ii) the right to impose the Default
Rate of interest under Section 3.1 of the Loan Agreement, or to collect interest accruing at such Default Rate that Lenders had
a lawful right to collect or apply with respect to any such Specified Default (the consents, waivers and modifications described
in clauses (2)(a)(i) – (a)(iii) and clause (2)(b), the "Closing Date Modifications").

 

Proposed Merger Transaction Consent

 

Agent and Lenders hereby
consent, notwithstanding anything contained in the Loan Agreement, the Term Loan Intercreditor Agreement or any other Loan Document
to the contrary, to the entry into and consummation by the Borrowers of the Proposed Merger Transaction in accordance with the
terms of the Merger Agreement; provided, that, it is expressly agreed and understood that no payment in respect of the "Company
Termination Fee" (as defined in the Merger Agreement) shall be made by Borrower or any other Loan Party, and no payment by
Borrower or any other Loan Party of such Company Termination Fee shall be accepted by Aytu or any of its affiliates, unless the
Payment Conditions are satisfied after giving effect to such payment (with it being further agreed and understood that any payment
of such Company Termination Fee shall be deemed to be a payment of the type described in clause (i) or (ii) of the definition of
Payment Conditions for purposes of such condition); provided, further, that, in the event such payment of the Company Termination
Fee is required to be deferred pursuant to the foregoing proviso, Borrowers may pay such Company Termination Fee at the time when
such Payment Conditions may otherwise be satisfied after giving effect thereto (or, if it has not been paid before such date, upon
the payment in full of all Obligations under, and termination of, the Loan Agreement). Notwithstanding any of the foregoing, Borrower
acknowledges that the above proviso does not relieve it, and nothing in this letter agreement constitutes a waiver of, its ultimate
obligation to Aytu to pay the Company Termination Fee pursuant to the requirements of the Merger Agreement (subject to the terms
hereof).

 

Specified Subordinated Note Consent

 

Agent and Lenders hereby
consent, notwithstanding anything contained in the Loan Agreement, the Term Loan Intercreditor Agreement or any other Loan Document
to the contrary, to incurrence of unsecured indebtedness under the Specified Subordinated Note provided that such indebtedness
is incurred on terms and conditions set forth in the form of note attached hereto as Exhibit C and subject to the terms
of subordination set forth in the form of subordination agreement attached hereto as Exhibit D (it being agreed and understood
that (1) the Specified Subordinated Note will have a scheduled maturity date at least 180 days after the Maturity Date under the
Loan Agreement, (2) payment in kind and repayment in the form of common stock of the Company or other qualified capital stock of
Company, or any convertible debt that is subject to the same subordination terms, shall be permitted, but no cash payments shall
be permitted to be made under the Specified Subordinated Note until the Obligations have been paid in full, and (3) the Specified
Subordinated Note shall be subject to a permanent standstill on remedies until the Obligations have been paid in full). The foregoing
is a limited consent and, except as expressly set forth in this letter agreement, the foregoing consent shall not constitute (a)
a modification or alteration of the terms, conditions or covenants of the Loan Agreement or any other Loan Document, or (b) a waiver,
release or limitation upon the exercise by Agent or any Lender of any of its rights, legal or equitable, thereunder.

 

    -2- 

     

    

 

Closing Date Modifications

 

In consideration of
the foregoing, Agent and Lenders hereby commit, in each case notwithstanding anything contained in the Loan Agreement, the Term
Loan Intercreditor Agreement or any other Loan Document, solely to (i) pursuant to a consent, waiver or other amendment to the
Loan Agreement and/or the Term Loan Intercreditor Agreement, respectively, in forms mutually acceptable to Agent, Borrowers and
the holders of the Term Loan Debt (the "Loan Modification Documents"), subject only to the conditions set
forth in the following paragraph, (a) consent to the change of control that will result from the consummation of the Proposed Merger
Transaction in accordance with the Merger Agreement, (b) consent to the making of the Specified Term Loan Prepayment to the extent
such prepayment is funded solely with proceeds of the Proposed Merger Transaction or otherwise provided by Aytu (and not, for the
avoidance of doubt, funded with any cash on hand of Company or any other Loan Party), (c) consent to the modifications to the Term
Loan Debt as contemplated under the Term Loan Debt Commitment Letter, and (d) irrevocably waive (1) the Specified Default (but
not, for the avoidance of doubt, any other Event of Default that may occur and be continuing at any time) and (2) the right to
impose the Default Rate of interest under Section 3.1 of the Loan Agreement, or to collect interest accruing at such Default Rate
that Lenders had a lawful right to collect or apply with respect to any such Specified Default (but not, for the avoidance of doubt,
any other Event of Default that may occur and be continuing at any time), and (ii) promptly and duly take, execute, acknowledge
and deliver (or cause each other applicable Person to take, execute, acknowledge and deliver) all such further acts, documents,
agreements and instruments as Borrower Representative and the holders of the Term Loan Debt may from time to time reasonably request
in order to carry out the intent and purposes of this letter agreement and the transactions contemplated hereby. The Loan Modification
Documents shall be negotiated in good faith. Except as otherwise agreed to by Agent and Lenders (but subject solely to the conditions
set forth herein), (A) the Loan Modification Documents shall be limited to such consents, amendments, waivers, supplements or other
modifications as may be necessary to carry out the express terms and provisions of this letter agreement and the transactions contemplated
hereby and (B) the Loan Agreement and the other Loan Documents shall otherwise remain unmodified and as in effect on the date hereof.

 

Conditions

 

Agent and Lenders'
commitment hereunder is subject solely to (i) consummation of the Proposed Merger Transaction in accordance with the terms of the
Merger Agreement without giving effect to any waiver, amendment or other modification to the Merger Agreement, other than any waiver,
amendment or other modifications that are not materially adverse to Agent and Lenders (as reasonably determined by Agent in good
faith), which amendment or other modification has not been approved in writing by Agent (which approval will not be unreasonably
withheld, conditioned or delayed), (ii) execution and delivery by each Loan Party of the Loan Modification Documents and all such
further documents, agreements and instruments as Agent may from time to time reasonably request in order to carry out the intent
and purposes of this letter agreement and the transactions contemplated hereby, (iii) execution and delivery of the definitive
documentation of the modifications described in the Term Loan Debt Commitment Letter on terms reasonably satisfactory to Agent
and Lenders, and (iv) no Loan Party shall have agreed to any waiver, consent or other modification that would result in the waiver
of payment or deferral of payment of the scheduled principal payment due on May 11, 2021 under the Term Loan Debt without the prior
written consent of Agent (which consent shall not be unreasonably withheld, delayed or conditioned). If, for any reason, the Merger
Agreement is terminated prior to the consummation of the Proposed Merger Transaction, then this letter agreement, other than the
consent under the heading "Specified Subordinated Note Consent", shall automatically terminate and shall be of no further
force or effect.

 

    -3- 

     

    

 

Miscellaneous

 

By their acceptance
of this letter agreement, each of Aytu and each Loan Party expressly acknowledge and agree that neither Agent nor any Lender has
waived, and has no intention of waiving, any Events of Default which may be continuing on the date hereof or any Events of Default
which may occur after the date hereof, or any of their rights and remedies in respect of any such Events of Default, and nothing
contained herein shall limit, condition, restrict or otherwise modify in any respect Agent's or any Lender's exercise of rights
and remedies under the Loan Agreement and the other Loan Documents as a result of any such Event of Default. Agent and Lenders
have not agreed to forbear with respect to any of their rights and remedies concerning any Event of Default which may have occurred
or be continuing as of the date hereof, or which may occur after the date hereof, and Agent and each Lender reserve the right,
in its discretion, to exercise any or all of its rights under the Credit Agreement, the other Loan Documents and applicable law
at any time.

 

Borrowers expressly
acknowledge and agree that Section 10.3 (Indemnity) and Section 15.7 (Expenses, Fee and Cost Reimbursement) of the Loan Agreement
apply to this letter agreement and the transactions contemplated hereby, and that such provisions shall survive termination or
expiration of this letter agreement regardless of whether the Proposed Merger Transaction is consummated.

 

This letter agreement
shall not be assignable by you without the prior written consent of Agent (and any purported assignment without such consent shall
be null and void), and is solely for the benefit of the parties hereto and is not intended to confer any benefits upon, or create
any rights in favor of, any person other than the parties hereto.

 

This letter may be
executed in any number of separate counterparts (including electronic and facsimile counterparts), each of which when executed
and delivered shall be deemed to be an original, and all of which shall collectively and separately constitute one agreement. Delivery
of an executed counterpart of a signature page of this letter agreement by facsimile or electronic mail shall be as effective as
delivery of a manually executed counterpart of this letter agreement. The words "execution," "signed," "signature,"
 "delivery," and words of like import in or relating to any document to be signed in connection with this letter agreement
and the transactions contemplated hereby shall be deemed to include electronic signatures, deliveries or the keeping of records
in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature,
physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for
in any applicable law, the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures
and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.

 

The terms of this letter
may not be changed except pursuant to a writing signed by the parties hereto. This letter shall be governed by the internal laws
of the State of New York (including Section 5-1401 of the General Obligations Law of the State of New York), without regard to
conflicts of laws principles that would require application of another law.

 

    -4- 

     

    

 

The parties hereto
consent and agree that the state or federal courts located in Cook County, State of Illinois, shall have exclusive jurisdiction
to hear and determine any claims or disputes between or among any of the parties hereto pertaining to this letter and the transactions
relating hereto. The parties hereto expressly submit and consent in advance to such jurisdiction in any action or suit commenced
in any such court, and hereby waive any objection, which each of the parties may have based upon lack of personal jurisdiction,
improper venue or inconvenient forum.

 

THE PARTIES HERETO,
TO THE EXTENT PERMITTED BY LAW, WAIVE ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, SUIT OR PROCEEDING ARISING OUT OF, IN CONNECTION
WITH OR RELATING TO, THIS LETTER AGREEMENT AND ANY TRANSACTION RELATED HERETO. THIS WAIVER APPLIES TO ANY ACTION, SUIT OR PROCEEDING
WHETHER SOUNDING IN TORT, CONTRACT OR OTHERWISE.

 

[Signature Pages Follow]

 

    -5- 

     

    

 

		Sincerely,
	 	 	 
	 	ENCINA BUSINESS CREDIT, LLC,
 as Agent
	 	 	 
	 	By:	/s/ Jean R. Elie
	 	Name:	Jean R. Elie
	 	Title:	Authorized Signatory

 

	 	ENCINA BUSINESS CREDIT SPV, LLC,

as sole Lender
	 	 	 
	 	By:	/s/ Jean R. Elie
	 	Name:	Jean R. Elie
	 	Title:	Authorized Signatory

 

	Agreed to and accepted as of the date first written above:	 
	 	 	 
	NEOS THERAPEUTICS, INC.,
 in its capacity as Borrower Representative	 
	 	 	 
	By:	/s/ Richard Eisenstadt	 
	Name:	Richard Eisenstadt	 
	Title:	Chief Financial Officer	 

 

	AYTU BIOSCIENCES, INC.	 
	 	 	 
	By:	/s/ Josh Disbrow	 
	Name:	Josh Disbrow	 
	Title:	Chief Financial Officer	 

 

[Signature Page to Commitment Letter]

 

    

     

    

 

Exhibit A

 

Form of Merger Agreement

 

(attached)

 

    

     

    

 

Exhibit B

 

Form of Term Loan Debt Commitment Letter

 

(attached)

 

    

     

    

 

Exhibit C

 

Form of Specified Subordinated Note

 

(attached)

 

    

     

    

 

Exhibit D

 

Form of Subordination Agreement

 

(attached)Exhibit 10.8

 

Execution
Version

 

 

 

LIMITED WAIVER TO LOAN AND SECURITY AGREEMENT

 

December 10, 2020

 

Via email

 

Neos Therapeutics, Inc.

2940 N. Hwy 360, Suite 400

Grand Prairie, Texas 75050

Attention: Richard Eisenstadt

Email: reisenstadt@neostx.com

 

		RE:	Loan and Security Agreement (as amended, restated or otherwise modified, the "Loan Agreement")
dated as of October 2, 2019, by and among NEOS THERAPEUTICS, INC., a Delaware corporation ("Company"),
NEOS THERAPEUTICS BRANDS, LLC, a Delaware limited liability company ("NT Brands"), NEOS THERAPEUTICS, LP, a Texas
limited partnership ("NT LP"; together with Company and NT Brands, each a "Borrower" and collectively
the "Borrowers"), NEOS THERAPEUTICS COMMERCIAL, LLC, a Delaware limited liability company ("NT Commercial"),
and PHARMAFAB TEXAS, LLC, a Texas limited liability company ("NT PharmaFab" together with NT Commercial each a
Loan Party Obligor and collectively, the “Loan Party Obligors”), the Lenders party hereto from time to time
and ENCINA BUSINESS CREDIT, LLC, as agent for the Lenders (in such capacity, "Agent").

 

Ladies & Gentlemen:

 

Capitalized terms used
in this Limited Waiver to Loan and Security Agreement (this "Waiver") but not defined herein shall have the meanings
assigned to them in the Loan Agreement. This Waiver is a Loan Document.

 

Subject to the terms
and conditions set forth below, Agent hereby irrevocably waives all breaches, Defaults and Events of Default under Section 7.15(a) of
the Loan Agreement solely to the extent resulting from the inclusion of a "going concern" qualification in the audited
financial statements of the Borrowers and Loan Party Obligors on a consolidated basis for the fiscal year ending December 31,
2020. The waiver in the preceding sentence shall terminate and be of no further force and effect upon the termination of that certain
Commitment Letter dated as of the date hereof by and among Borrower Representative, Aytu Biosciences, Inc., Agent and sole
Lender (the "Encina Commitment Letter") in accordance with its terms.

 

    

     

    

 

The foregoing is a
limited waiver and, except as expressly set forth in this Waiver, the foregoing limited waiver shall not constitute (a) a
modification or alteration of the terms, conditions or covenants of the Loan Agreement or any other Loan Document, or (b) a
waiver, release or limitation upon the exercise by Agent or any Lender of any of its rights, legal or equitable, thereunder.

 

Each Loan Party Obligor
hereby represents, warrants and covenants to Agent that:

 

		a.	Each Loan Party Obligor is validly existing as a corporation, limited liability company or limited
partnership, as applicable, and is in good standing under the laws of the jurisdiction of its incorporation, organization or formation,
as applicable. Each Loan Party Obligor (i) has full power and authority (and all governmental licenses, authorizations, permits
(including all Health Care Permits and other Permits), consents and approvals) to (A) own its properties and conduct its business
and (B) to (x) enter into, and perform its obligations under, this Waiver and the other Loan Documents and (y) consummate
the transactions contemplated under this Waiver and the other Loan Documents, and (ii) is duly qualified as a foreign corporation,
limited liability company or limited partnership, as applicable, and licensed and in good standing, under the laws of each jurisdiction
where its ownership, lease or operation of property or the conduct of its business requires such qualification or license, in each
case of this clause (ii), where the failure to be so qualified, licensed or in good standing could reasonably be expected, individually
or in the aggregate, to result in a Material Adverse Effect;

 

		b.	The execution, delivery and performance of this Waiver and the other Loan Documents, in each case,
have been duly authorized by each Loan Party Obligor, and no further consent or authorization is required by any Loan Party Obligor,
any Loan Party Obligor’s board of directors (or other equivalent governing body) or the holders of any Loan Party Obligor’s
Stock;

 

		c.	Immediately after giving effect to this Waiver, the representations and warranties of the Loan
Party Obligors contained in the Loan Documents shall, in each case, be true, correct and complete in all material respects (without
duplication of any materiality provision contained therein) on and as of the date hereof (or any earlier date with respect to which
any such representation or warranty relates); and

 

		d.	Immediately after giving effect to this Waiver (including Section 2 hereof), no Default or
Event of Default shall have occurred and be continuing.

 

This Waiver may be
executed in several counterparts, and by each party hereto on separate counterparts, each of which and any photocopies, facsimile
copies and other electronic methods of transmission thereof shall be deemed an original, but all of which together shall constitute
one and the same agreement.

 

This Waiver is made
solely for the benefit of Borrowers and Loan Party Obligors and no other Person may rely on or have shall have any right, benefit
or interest under or because of this Waiver.

 

Each Borrower and each
other Loan Party Obligor hereby reaffirms its obligations under each Loan Document to which it is a party, as each may have been
amended on or prior to the date hereof (the "Reaffirmed Agreements"). Each Borrower and each other Loan Party
Obligor hereby further agrees that each Reaffirmed Agreement to which it is a party shall remain in full force and effect following
the execution and delivery of this Waiver and that all references in any of the Reaffirmed Agreements to which it is a party to
the "Loan Agreement" shall be deemed to refer to the Loan Agreement, as supplemented by this Waiver and as amended or
modified from time to time hereafter. Except as expressly set forth herein, each of the Reaffirmed Agreements shall remain unmodified
and in full force and effect.

 

    -2-

     

    

 

Each Borrower and each
other Loan Party Obligor on behalf of itself and its successors, assigns, heirs and other legal representatives, hereby absolutely,
unconditionally and irrevocably releases, remises and forever discharges Agent and each Lender and any and all Participants and
Affiliates, and their respective successors and assigns, and their respective directors, members, managers, officers, employees,
attorneys and agents, including without limitation each Agent-Related Person, and any other Person affiliated with or representing
Agent or any Lender (collectively, the "Released Parties") of and from any and all liability, including all actual
or potential claims, demands or causes of action of any kind, nature or description whatsoever, whether arising in law or equity
or under contract or tort or under any state or federal law or otherwise, which any Borrower or any Loan Party or any of their
successors, assigns or other legal representatives has had, now has or has made claim to have against any of the Released Parties
for or by reason of any act, omission, matter, cause or thing whatsoever, including any liability arising from acts or omissions
pertaining to the transactions contemplated by this Waiver, whether based on errors of judgment or mistake of law or fact, from
the beginning of time to and including the date hereof, whether such claims, demands and causes of action are matured or known
or unknown.

 

Each Borrower and each
other Loan Party Obligor expressly acknowledges and agrees that Section 10.3 (Indemnity) and Section 15.7 (Expenses,
Fee and Cost Reimbursement) of the Loan Agreement apply to this letter agreement and the transactions contemplated hereby.

 

THIS WAIVER SHALL BE
GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAW OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED
THEREIN WITHOUT REGARD TO CONFLICT OF LAW PRINCIPLES. FURTHER, THE LAW OF THE STATE OF NEW YORK SHALL APPLY TO ALL DISPUTES OR
CONTROVERSIES ARISING OUT OF OR CONNECTED TO OR WITH THIS WAIVER WITHOUT REGARD TO CONFLICT OF LAW PRINCIPLES.

 

[signature pages follow]

 

    -3-

     

    

 

	 	Encina Business Credit, LLC,
	 	as Agent
	 	 
	 	By:	/s/ John D. Whetstone
	 	Name:	John D. Whetstone
	 	Title:	EVP
	 	 
	 	 
	 	Encina Business Credit SPV, LLC,
	 	as sole Lender
	 	 
	 	By:	/s/ John D. Whetstone
	 	Name:	John D. Whetstone
	 	Title:	EVP

 

Signature Page to
Limited Waiver

 

    

     

    

 

	 	AGREED TO :
	 	 
	 	 
	 	Borrowers:
	 	 
	 	NEOS THERAPEUTICS, INC.
	 	 
	 	 
	 	By:	/s/ Richard Eisenstadt
	 	Name:	Richard Eisenstadt
	 	Its:	Chief Financial Officer
	 	 
	 	NEOS THERAPEUTICS BRANDS, LLC  
	 	 
	 	 
	 	By:	/s/ Richard Eisenstadt
	 	Name:	Richard Eisenstadt
	 	Its:	Chief Financial Officer
	 	 
	 	NEOS THERAPEUTICS, LP  
	 	 
	 	 
	 	By:	/s/ Richard Eisenstadt
	 	Name:	Richard Eisenstadt
	 	Its:	Chief Financial Officer
	 	 
	 	Loan Party Obligors:
	 	 
	 	NEOS THERAPEUTICS COMMERCIAL, LLC  
	 	 
	 	 
	 	By:	/s/ Richard Eisenstadt
	 	Name:	Richard Eisenstadt
	 	Its:	Chief Financial Officer
	 	 
	 	NEOS THERAPEUTICS, LP  
	 	 
	 	 
	 	By:	/s/ Richard Eisenstadt
	 	Name:	Richard Eisenstadt
	 	Its:	Chief Financial Officer
	 	 

 

Signature Page to
Limited Waiver

 

    

     

    

 

	 	PHARMAFAB TEXAS, LLC  
	 	 
	 	 
	 	By:	/s/ Richard Eisenstadt
	 	Name:	Richard Eisenstadt
	 	Its:	Chief Financial Officer

 

Signature Page to
Limited Waiver

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}]]